Published in J Clin Hypertens (Greenwich) on June 10, 2013
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | NCT00000542
Lipid-lowering in African Americans in ALLHAT-optimism bias? J Clin Hypertens (Greenwich) (2013) 1.06
Comparison of the efficacy and safety of intensive-dose and standard-dose statin treatment for stroke prevention: A meta-analysis. Medicine (Baltimore) (2016) 0.75
What does ALLHAT tell us about dyslipidemia from the hypertension specialist perspective? J Clin Hypertens (Greenwich) (2013) 0.75
Author response to lipid-lowering in African Americans in ALLHAT-optimism bias? J Clin Hypertens (Greenwich) (2013) 0.75
Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet (2008) 8.53
Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med (2007) 7.96
Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens (1996) 4.66
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 3.59
The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J (2008) 2.65
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease. Am J Kidney Dis (2005) 2.36
Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant (2005) 2.01
Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet (2002) 1.89
Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension (2003) 1.85
Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. Am J Cardiol (1995) 1.81
Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med (2002) 1.78
Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Kidney Dis (2008) 1.68
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (2009) 1.52
Disparities in screening for and awareness of high blood cholesterol--United States, 1999-2002. MMWR Morb Mortal Wkly Rep (2005) 1.27
Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy. Am Heart J (2006) 1.12
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study. Pharmacogenet Genomics (2008) 1.12
Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich) (2011) 1.04
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med (2010) 21.49
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 17.18
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med (2011) 15.30
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care. J Gerontol A Biol Sci Med Sci (2004) 12.46
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 9.03
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Visualizing genomes: techniques and challenges. Nat Methods (2010) 6.66
Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum (2004) 6.46
Erectile dysfunction and subsequent cardiovascular disease. JAMA (2005) 6.22
Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich) (2002) 6.03
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension (2009) 4.26
Estimating global "blue carbon" emissions from conversion and degradation of vegetated coastal ecosystems. PLoS One (2012) 4.24
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care (2010) 4.10
Measuring socio-economic position for epidemiological studies in low- and middle-income countries: a methods of measurement in epidemiology paper. Int J Epidemiol (2012) 3.93
Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA (2005) 3.89
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
In-hospital and 1-year mortality in patients undergoing early surgery for prosthetic valve endocarditis. JAMA Intern Med (2013) 3.72
Widespread genomic signatures of natural selection in hominid evolution. PLoS Genet (2009) 3.68
Depressive symptoms, vascular disease, and mild cognitive impairment: findings from the Cardiovascular Health Study. Arch Gen Psychiatry (2006) 3.61
Cognitive function, gait speed decline, and comorbidities: the health, aging and body composition study. J Gerontol A Biol Sci Med Sci (2007) 3.61
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Poverty, child undernutrition and morbidity: new evidence from India. Bull World Health Organ (2005) 3.30
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol (2011) 3.25
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 2.98
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol (2011) 2.89
Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich) (2012) 2.85
Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension (2013) 2.83
Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med (2006) 2.81
Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation (2004) 2.73
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology (2013) 2.61
The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials (2011) 2.59
Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol (2005) 2.52
Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation (2008) 2.51
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol (2003) 2.47
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res (2007) 2.32
The DNA sequence and biology of human chromosome 19. Nature (2004) 2.29
The Lifestyle Interventions and Independence for Elders Study: design and methods. J Gerontol A Biol Sci Med Sci (2011) 2.26
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25